Specific and sensitive detection of prostate cancer using urine sediment DNA
Carol Lovegrove
This article has no abstract so we have provided the first paragraph of the full text.
Treatment of prostate cancer can be curative but depends on early detection. Although prostate-specific antigen (PSA) is widely regarded as one of the best serum tumor markers, PSA level alone is neither sensitive nor specific enough for a definitive diagnosis, and transrectal biopsies are needed to confirm prostate cancer. A recent study has demonstrated that the detection of aberrant promoter methylation using quantitative methylation-specific polymerase chain reaction (QMSP) in urine sediment DNA offers potential as a specific, sensitive and noninvasive test for prostate cancer.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.